department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Xencor Inc ($XNCR) · pharmadog

PUBLIC COMPANY

$XNCRXencor Inc

Pasadena, CA, USupdated 1h ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

1

marketed

0

phase 3

0

catalysts ytd

2

approvals ytd

0

recalls ytd

0

Pipeline(1)

pipeline depth1 products

1Phase 1

Adenocarcinoma Of The Gastroesophageal Junction

Upcoming

no upcoming catalysts on record

Recent(90d)

earnings (1)

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Xencor Inc jobs →

News

no news has mentioned this company yet

identifiers

ticker

$XNCR

SEC CIK

0001326732

country

US

source

sec_tickers

top tags

mentioned in

0news items

entity-linker matched

Xencor Inc earnings

Data sources

SEC EDGAR · openFDA

last refreshed 14m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Insider activity

source: SEC Form 4

90d open-market buys

$0

0 transactions

90d open-market sells

$43K

1 transaction

net (buys − sells)

−$43K

non-derivative only

open-market buys + sells

Apr 10, 26SELLCornelissen Bart Jan· SR. VICE PRESIDENT & CFO3,499 sh @ $12.29−$43K↗
Mar 6, 26SELLDahiyat Bassil I· PRESIDENT & CEO6,606 sh @ $11.02−$73K↗
Mar 6, 26SELLDesjarlais John R· SR. VICE PRESIDENT & CSO2,502 sh @ $11.02−$28K↗
Mar 6, 26SELLEckert Celia· SVP, GENERAL COUNSEL1,767 sh @ $11.02−$19K↗
Mar 5, 26SELLDahiyat Bassil I· PRESIDENT & CEO14,870 sh @ $11.25−$167K↗
Mar 5, 26SELLDesjarlais John R· SR. VICE PRESIDENT & CSO4,118 sh @ $11.25−$46K↗
Mar 5, 26SELLEckert Celia· SVP, GENERAL COUNSEL3,244 sh @ $11.25−$36K↗
Mar 5, 26SELLCornelissen Bart Jan· SR. VICE PRESIDENT & CFO2,517 sh @ $11.25−$28K↗
Mar 3, 26SELLDahiyat Bassil I· PRESIDENT & CEO6,758 sh @ $11.90−$80K↗
Mar 3, 26SELLDesjarlais John R· SR. VICE PRESIDENT & CSO2,663 sh @ $11.90−$32K↗
Mar 3, 26SELLEckert Celia· SVP, GENERAL COUNSEL1,492 sh @ $11.90−$18K↗

routine RSU / option mechanics (6)

Mar 2, 26grantDesjarlais John R · SR. VICE PRESIDENT & CSO24,907 sh
Mar 2, 26grantDesjarlais John R · SR. VICE PRESIDENT & CSO149,440 sh
Mar 2, 26grantCornelissen Bart Jan · SR. VICE PRESIDENT & CFO19,458 sh
Mar 2, 26grantCornelissen Bart Jan · SR. VICE PRESIDENT & CFO116,750 sh
Mar 2, 26grantEckert Celia · SVP, GENERAL COUNSEL18,680 sh

$XNCR15.00-2.47%

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Mar 2, 26

grant

Eckert Celia · SVP, GENERAL COUNSEL

112,080 sh

$XNCR15.00-2.47%